Odronextamab: a bispecific antibody for follicular lymphoma
A newly approved antibody therapy offers follicular lymphoma patients a chemo-free treatment option with strong response rates in early trials.
This review synthesizes the clinical development of odronextamab, a CD20xCD3 bispecific antibody recently approved by the EMA for relapsed/refractory follicular lymphoma based on ELM-1 and ELM-2 trial data. Ongoing Phase III OLYMPIA studies are evaluating its use in earlier treatment lines and combinations, positioning it among emerging chemo-free options alongside mosunetuzumab and epcoritamab.
What the study was
- Study design
- Narrative review
- Population
- Relapsed/refractory follicular lymphoma, including POD24 patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Expert Opinion on Investigational Drugs
Why it surfaced
EMA-approved bispecific antibody with phase III data underway; relevant to R/R FL management where chemo-free approaches are transforming care. Review quality reflects the summarized trial data rather than new primary data, capping score at 7.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.